

NHL: Mantle Cell Lymphoma Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

Pathology: _____ Stage: _____

Line of Therapy: __1st Line __2nd Line __3rd Line __3rd Line+ __Maint ECOG Performance Status: _____ ICD-10 Code: _____

Biomarkers/Characteristics: (select all that apply)

CD20 status: __Negative __Positive HIV associated lymphoma: __No __Yes Transplant Candidate: __No __Yes

First Line of Therapy (1st Line) | ASCT Candidates

Alternating R-CHOP/R-DHAP: cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine (Vincasar), prednisone, rituximab (Rituxan) alternating with dexamethasone, cisplatin, cytarabine (Ara-C), and rituximab (Rituxan)

Nordic Regimen: dose intensified rituximab (Rituxan), cyclophosphamide, vincristine (Vincasar), doxorubicin (Adriamycin), prednisone alternating with rituximab (Rituxan) and high dose cytarabine (Ara-C)

First Line of Therapy (1st Line) | Not an ASCT Candidate

BR: bendamustine (Bendeke, Treanda) and rituximab (Rituxan)

Second and Subsequent Lines of Therapy (2nd Line+)

BR: bendamustine (Bendeke, Treanda) and rituximab (Rituxan)

Bortezomib (Velcade)

Ibrutinib (Imbruvica)

Lenalidomide (Revlimid)

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether nonposed services will be covered.